Entresto is a brand name for a medication that combines sacubitril and valsartan [1]. It is used to reduce the risk of cardiovascular death and hospitalization for heart failure in certain patients [2].
What is the generic name for Entresto?
The generic name for Entresto is sacubitril/valsartan [1]. This indicates the two active pharmaceutical ingredients that make up the medication.
How does Entresto work?
Entresto belongs to a class of drugs called Angiotensin Receptor-Neprilysin Inhibitors (ARNI) [2]. Sacubitril works by inhibiting neprilysin, an enzyme that breaks down natriuretic peptides. These peptides help to reduce blood pressure and promote the excretion of salt and water. Valsartan is an angiotensin II receptor blocker (ARB), which also helps to lower blood pressure by blocking the effects of angiotensin II [1]. By combining these mechanisms, Entresto helps to reduce the strain on the heart [2].
When did Entresto patents expire?
Information on specific patent expiry dates for Entresto can be found on DrugPatentWatch.com [3]. Patents protect the exclusive rights of the drug manufacturer for a certain period, after which generic versions may become available.
Can I get a generic version of Entresto?
As of current information, a generic version of Entresto has been approved in the United States [4]. The availability of generic options can depend on patent status and regulatory approvals.
Who makes Entresto?
Entresto is manufactured by Novartis [1].
What are the side effects of Entresto?
Common side effects associated with Entresto include low blood pressure, high potassium levels, dizziness, cough, and kidney problems [2]. Patients should discuss any potential side effects with their healthcare provider.
What conditions does Entresto treat?
Entresto is prescribed for patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) to decrease the risk of cardiovascular death and heart failure hospitalization [2].
How does Entresto compare to other heart failure medications?
Entresto represents a different mechanism of action compared to traditional heart failure treatments like ACE inhibitors or ARBs alone. Clinical trials have shown Entresto to be more effective than enalapril (an ACE inhibitor) in reducing cardiovascular death and heart failure hospitalizations in patients with HFrEF [2].
What are the risks of taking Entresto?
Risks associated with Entresto include angioedema, a severe allergic reaction that can cause swelling of the face, lips, tongue, or throat, which can be life-threatening. It can also cause a significant drop in blood pressure, especially in patients who are volume or salt depleted, or those taking diuretics. Patients with a history of angioedema related to ACE inhibitors or ARBs should not take Entresto. It is also contraindicated during pregnancy due to the risk of fetal harm or death [2].
Sources
1. Entresto. (n.d.). Retrieved from https://www.entresto.com/
2. Entresto. (n.d.). Retrieved from https://www.novartis.com/our-impact/our-products/entresto
3. DrugPatentWatch. (n.d.). Retrieved from https://drugpatentwatch.com/
4. FDA Approves First Generic Versions of Entresto. (n.d.). Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety/approved-first-generic-versions-entresto